{
  "docId": "019de074-d961-7389-a20b-cd17e719b042",
  "docSlug": "eb72a4aa6f7d8bed68bc577a406605bf",
  "documentTitle": "BioAtla | Investor Presentation Deck | 44 slides",
  "authorId": "bioatla",
  "authorName": "BioAtla",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-05-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 21,
  "pageCount": 44,
  "prevPage": 20,
  "nextPage": 22,
  "slideType": "traction",
  "function": "show_traction",
  "density": "dense",
  "nDataPoints": 14,
  "notes": "Includes specific clinical trial safety metrics and footnotes regarding data definitions.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-d961-7389-a20b-cd17e719b042/21",
  "deckHref": "/decks/019de074-d961-7389-a20b-cd17e719b042",
  "deckJsonHref": "/decks/019de074-d961-7389-a20b-cd17e719b042.json",
  "deckAnchorHref": "/decks/019de074-d961-7389-a20b-cd17e719b042#slide-21",
  "components": [
    {
      "bbox": {
        "h": 0.5,
        "w": 0.35,
        "x": 0.6,
        "y": 0.25
      },
      "kind": "list",
      "text": "No treatment-related deaths; Few treatment-related SAEs; Few AEs leading to treatment discontinuation; No clinically meaningful on-target toxicity; Differentiated profile.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8cc23759-e0af-4444-8ae0-cc923a474f49",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.8,
        "x": 0.03,
        "y": 0.9
      },
      "kind": "source-note",
      "text": "Interim data- Data cut-off of Dec 21, 2022. CTCAE definitions and specific event notes.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8a6655c4-a388-455d-a664-ccb415ad26ab",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.5,
        "x": 0.04,
        "y": 0.21
      },
      "kind": "table",
      "text": "Safety table comparing BA3011 and BA3011 + Opdivo across various AE categories.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1cd3d0f5-04db-4aa5-817e-025df561e5d9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.8,
        "x": 0.03,
        "y": 0.08
      },
      "kind": "title",
      "text": "Promising safety and tolerability profile continues to emerge in NSCLC",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a0c7d14c-896a-4a29-80e7-64611088e1ed",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.3,
        "x": 0.03,
        "y": 0.14
      },
      "kind": "title",
      "text": "Phase 2 at the RP2D 1.8 mg/kg Q2W",
      "attrs": null,
      "subkind": "subtitle",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f02810f9-3f13-45f0-b48b-ffc0cfc51597",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Table data",
      "slug": "table-data",
      "agent": null,
      "layer": "slide",
      "matchId": "afcd0499-8d4f-47de-a594-010f6ad3ab8a",
      "evidence": "Safety table comparing BA3011 and BA3011 + Opdivo across various AE categories.",
      "confidence": 0.8
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 21,
      "from": 11,
      "beatId": "9dc7924a-cf61-4c29-9fd6-e666a2b3daec",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Traction",
      "beatSlug": null,
      "evidence": "slides 11-21 provide traction information",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [
    {
      "to": 21,
      "from": 11,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "e3b4bfda-4f05-4903-9455-c38c0aa043e5",
      "evidence": "slides 11-21 provide data on the effectiveness of CABs",
      "position": 0,
      "objective": "To highlight the potential benefits of CABs in cancer therapy",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}